Elevance Health, Inc. $ELV Shares Sold by Power Wealth Management LLC

Posted by Brian Himes on Sep 4th, 2026

Power Wealth Management LLC trimmed its holdings in Elevance Health, Inc. (NYSE:ELV – Free Report) by 29.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,315 shares of the company’s stock after selling 1,843 shares during the quarter. Elevance Health comprises approximately 0.6% of Power Wealth Management LLC’s portfolio, making the stock its 26th largest holding. Power Wealth Management LLC’s holdings in Elevance Health were worth $1,669,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. WealthCollab LLC increased its holdings in shares of Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after purchasing an additional 27 shares during the last quarter. Kilter Group LLC acquired a new position in Elevance Health during the second quarter worth $28,000. Kemnay Advisory Services Inc. acquired a new position in Elevance Health during the fourth quarter worth $31,000. J.Safra Asset Management Corp purchased a new stake in Elevance Health in the 4th quarter valued at $32,000. Finally, Main Street Group LTD acquired a new stake in shares of Elevance Health in the 1st quarter worth $39,000. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Elevance Health Stock Up 2.3%

Shares of NYSE ELV opened at $415.05 on Friday. The firm has a market cap of $90.01 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 2.11 and a beta of 0.69. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 52-week low of $274.84 and a 52-week high of $436.24. The business’s 50 day moving average is $396.48 and its two-hundred day moving average is $364.27.

Elevance Health (NYSE:ELV – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 14.64% and a net margin of 2.47%.The company had revenue of $49.83 billion for the quarter, compared to analysts’ expectations of $48.88 billion. During the same period in the prior year, the firm earned $8.84 earnings per share. The firm’s revenue was up .8% compared to the same quarter last year. Research analysts predict that Elevance Health, Inc. will post 27.18 EPS for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 annualized dividend and a yield of 1.7%. Elevance Health’s dividend payout ratio is presently 30.58%.

Insider Buying and Selling

In other Elevance Health news, Director Robert Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. JPMorgan Chase & Co. lifted their price target on Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Robert W. Baird upped their price objective on shares of Elevance Health from $331.00 to $393.00 and gave the company a “neutral” rating in a report on Thursday, July 16th. Barclays cut their price objective on shares of Elevance Health from $480.00 to $457.00 and set an “overweight” rating for the company in a research report on Thursday, July 16th. UBS Group boosted their target price on shares of Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a report on Friday, May 22nd. Finally, Truist Financial increased their price target on shares of Elevance Health from $450.00 to $475.00 and gave the company a “buy” rating in a research note on Tuesday, July 14th. Fifteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $440.90.

Read Our Latest Report on Elevance Health

About Elevance Health

(Free Report)

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.